icon-    folder.gif   Conference Reports for NATAP  
 
  20th Conference on Retroviruses and
Opportunistic Infections
Atlanta, GA March 3 - 6, 2013
Back grey_arrow_rt.gif
 
 
 
Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers
 
 
  Reported by Jules Levin
20th Conference on Retroviruses and Opportunistic Infections, March 36, 2013
 
John P Sabo,1 Jens Kort,1 Manuel Haschke,2 Charles Ballow,3 Birgit Girlich,4 Ulrich Feifel,5 Benjamin Lang,6 Michael Schobelock,1 Mabrouk Elgadi7 1Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, USA; 2University Hospital Basel, Basel, Switzerland; 3Buffalo Clinical Research Center, Buffalo, NY, USA; 4Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; 5Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Ingelheim, Germany; 6Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Biberach, Germany; 7Boehringer Ingelheim (Canada) Ltd, Burlington, Ontario, Canada

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif